$17.39
+0.88(5.30%)
Mkt Cap $1.2B
$6.25
$61.99
52-Week Range
At A Glance
1
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies.
2
Most recently: Entry into a Material Definitive Agreement On February 20, 2026 (the “Amendment Closing Date”), MoonLake Immunotherapeutics (the “Company”), as a guarantor, ent (2026-02-23).
$1.2B
Market Cap
—
Revenue
-$253M
Net Income
Employees100
Fundamentals
How The Business Makes Money
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Industry Biotechnology
Activity
What Changed Recently
Company Profile
CIK0001821586
ISINKY61559X1045
CUSIP61559X104
Phone41 415108022
AddressDorfstrasse 29, Zug, 6300, CH
SEC EDGAR